Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01411657 · ClinicalTrials.gov registry record · Phase 1
NT-501 CNTF Implant for Ischemic Optic Neuropathy: Safety, Neuroprotection and Neuroenhancement
A Phase 1 study, sponsored by Jeffrey L Goldberg.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT01411657 is a Phase 1 study that has completed, run by Jeffrey L Goldberg. The registered enrollment target is 11 participants.
The verdict
NCT01411657, a Phase 1 study, has completed, sponsored by Jeffrey L Goldberg.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
Ciliary Neurotrophic Factor (CNTF) has been demonstrated in multiple preclinical models to enhance survival and regeneration of retinal ganglion cells, the retinal neurons injured in diseases like ischemic optic neuropathy/optic nerve stroke. We hypothesize that CNTF delivery to the human eye will provide neuroprotection (prevent loss of vision) and neuroenhancement (improve vision indices) in ischemic optic neuropathy. Patients in the trial will receive an NT-501 CNTF implant (made by Neurotech) into one eye, and will be carefully followed to evaluate safety and efficacy.
Interventions
- DRUG NT-501 CNTF Implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-04 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01411657
The ClinicalTrials.gov registry entry for NCT01411657 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jeffrey L Goldberg, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NT-501 CNTF Implant is the first listed.
NCT01411657 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01411657 about?
NCT01411657 is a clinical study titled "NT-501 CNTF Implant for Ischemic Optic Neuropathy: Safety, Neuroprotection and Neuroenhancement". Ciliary Neurotrophic Factor (CNTF) has been demonstrated in multiple preclinical models to enhance survival and regeneration of retinal ganglion cells, the retinal neurons injured in diseases like ischemic optic neuropathy/optic nerve stroke. We hypothesize that CNTF delivery to the human eye will p...
What is the current status of trial NCT01411657?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2011-04. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01411657?
The interventions under investigation include: NT-501 CNTF Implant (DRUG).
Who is sponsoring clinical trial NCT01411657?
This trial is sponsored by Jeffrey L Goldberg, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.